Nanomedicine potential for endometriosis treatment

Moataz Dowaidar
2023 · doi:10.5281/zenodo.8165310 · W6931727924
article OA: green CC0
🔓 Open OA copy Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-08-11 ⓘ

Nanotechnologies offer a promising, though early-stage, approach to delivering therapeutic compounds directly to endometriosis sites, potentially improving treatment efficacy and patient compliance.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by gpt-5.6-luna, 2026-08-12 · read from full text ⓘ

This paper reviews alternative and nanotechnology-based drug-delivery strategies for endometriosis treatment, including LNG-IUSs, depot medroxyprogesterone acetate, vaginal rings, danazol, aromatase inhibitors, and nanoparticle bioconjugates. It notes that LNG-IUSs and depot formulations have been evaluated in numerous randomized controlled trials and may improve adherence and satisfaction, whereas vaginal-ring and nanomedicine approaches remain largely exploratory. Proposed nanotechnologies could deliver anti-inflammatory, antioxidant, anti-angiogenic, and immunomodulatory agents directly to endometriotic lesions, but available evidence is limited to early proof-of-concept studies, and no nanomedicine has yet been tested clinically for endometriosis; findings from mouse models may not predict clinical efficacy. This paper is centrally about endometriosis — the potential of nanomedicine and alternative drug-delivery systems for its treatment.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Contraception has previously provided alternative medication delivery techniques for the treatment of endometriosis. Only LNG-IUSs and depot formulation (DMPA), however, have been studied in numerous RCTs to treat patients. These approaches tend to enhance patient compliance and satisfaction when compared to other conventional treatment alternatives. Nanotechnologies are potential new drug delivery techniques that have been shown to deliver compounds with a particular therapeutic impact. However, the information is limited and preliminary. Endometriosis research has identified the patients who could benefit most from this kind of medication administration. No one has ever been used in a clinical study to treat endometria. Alternative medication delivery techniques may help to enhance compliance, effectiveness, and the development of novel treatment approaches. The use of vaginal rings as a unique and alternative medication delivery route for AIs, as well as the experience with danazol, are examples. The vaginal ring has been studied as a new medication delivery mechanism for danazol and aromatase inhibitors. Nanotechnologies are made up of bioconjugates that deliver anti-inflammatory, antioxidant, anti-angiogenic, and immunomodulating chemicals directly to the illness site. At this early stage of proof-of-concept, the evidence is limited and tentative. Clinical effectiveness can not be predicted using mouse models.
Full text 1,647 characters · extracted from oa-doi-fallback · click to expand
Nanomedicine potential for endometriosis treatment Authors/Creators Description Contraception has previously provided alternative medication delivery techniques for the treatment of endometriosis. Only LNG-IUSs and depot formulation (DMPA), however, have been studied in numerous RCTs to treat patients. These approaches tend to enhance patient compliance and satisfaction when compared to other conventional treatment alternatives. Nanotechnologies are potential new drug delivery techniques that have been shown to deliver compounds with a particular therapeutic impact. However, the information is limited and preliminary. Endometriosis research has identified the patients who could benefit most from this kind of medication administration. No one has ever been used in a clinical study to treat endometria. Alternative medication delivery techniques may help to enhance compliance, effectiveness, and the development of novel treatment approaches. The use of vaginal rings as a unique and alternative medication delivery route for AIs, as well as the experience with danazol, are examples. The vaginal ring has been studied as a new medication delivery mechanism for danazol and aromatase inhibitors. Nanotechnologies are made up of bioconjugates that deliver anti-inflammatory, antioxidant, anti-angiogenic, and immunomodulating chemicals directly to the illness site. At this early stage of proof-of-concept, the evidence is limited and tentative. Clinical effectiveness can not be predicted using mouse models. Files Files (65.1 kB) | Name | Size | Download all | |---|---|---| | md5:9e295a61a76b9bd4cf982b5bf5b016d9 | 65.1 kB | Download |

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-05-10T10:49:45.548917+00:00
License: CC0 · commercial use OK